Myhibbin
Myhibbin ingredients
| Active ingredient | Strength |
|---|---|
| Mycophenolate Mofetil | 200 mg/mL |
What Myhibbin is used for
The FDA lists the approved uses on the official label (below). In the EU, mycophenolate mofetil is approved as CellCept for:
CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Myhibbin
- Generic name
- Mycophenolate mofetil
- Made by
- Azurity Pharmaceuticals, Inc.
- Forms
- Suspension
- Given
- Oral
- Drug class
- Antimetabolite Immunosuppressant
- FDA approval
- New drug application (NDA) NDA216482
- On the US market since
- 2024
Official information
- MedlinePlus drug information (search for Mycophenolate mofetil)
In India
- Mycophenolate mofetil: 80 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Myhibbin?
Myhibbin (Mycophenolate mofetil) is a cancer medicine made by Azurity Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Myhibbin?
Myhibbin contains Mycophenolate Mofetil (200 mg/mL).
Is Myhibbin approved in Europe?
The same active substance is approved in the EU as CellCept.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA